4.6 Article

The Specialized Proresolving Mediator 17-HDHA Enhances the Antibody-Mediated Immune Response against Influenza Virus: A New Class of Adjuvant?

Journal

JOURNAL OF IMMUNOLOGY
Volume 193, Issue 12, Pages 6031-6040

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1302795

Keywords

-

Categories

Funding

  1. National Institutes of Health [AI103690, ES01247, GM038765, RO1 AI077719, R21NS075611, R03AI099681]
  2. University of Rochester Center for Biodefense Immune Modeling Grant [HHSN272201000055C]
  3. National Institute of Allergy and Infectious Diseases Center of Excellence for Influenza Research and Surveillance Grant [HHSN266200700008C]
  4. [T90 DE021985]
  5. [T32 AI007285]
  6. [T32 HL066988]

Ask authors/readers for more resources

Influenza viruses remain a critical global health concern. More efficacious vaccines are needed to protect against influenza virus, yet few adjuvants are approved for routine use. Specialized proresolving mediators (SPMs) are powerful endogenous bioactive regulators of inflammation, with great clinical translational properties. In this study, we investigated the ability of the SPM 17-HDHA to enhance the adaptive immune response using an OVA immunization model and a preclinical influenza vaccination mouse model. Our findings revealed that mice immunized with OVA plus 17-HDHA or with H1N1-derived HA protein plus 17-HDHA increased Ag-specific Ab titers. 17-HDHA increased the number of Ab-secreting cells in vitro and the number of HA-specific Ab-secreting cells present in the bone marrow. Importantly, the 17-HDHA-mediated increased Ab production was more protective against live pH1N1 influenza infection in mice. To our knowledge, this is the first report on the biological effects of omega-3-derived SPMs on the humoral immune response. These findings illustrate a previously unknown biological link between proresolution signals and the adaptive immune system. Furthermore, this work has important implications for the understanding of B cell biology, as well as the development of new potential vaccine adjuvants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available